This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riely, G. J. Articles by Miller, V. A. Search for Related Content PubMed PubMed Citation Articles by Riely, G. J. Articles by Miller, V. A.

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer

Authors' Affiliation: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College of Cornell University, New York, New York

Requests for reprints: Vincent A. Miller, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10022. Fax: 212-794-4357; E-mail: millerv{at}mskcc.org.

Several drugs currently in development target the vascular endothelial growth factor (VEGF) pathway, a validated target in the treatment of non–small cell lung cancer (NSCLC). Most clinical trial data generated to date have been with either bevacizumab, a monoclonal antibody to VEGF, or small-molecule inhibitors of VEGF receptor (VEGFR) tyrosine kinase activity (sunitinib, sorafenib, and ZD6474). VEGF Trap, an engineered soluble receptor made from extracellular domains of VEGFR1 and VEGFR2, binds to all isoforms of VEGF and to placental growth factor. VEGF Trap binds to VEGF-A and VEGF-B with markedly higher affinity than bevacizumab. The toxicities seen in phase I trials of s.c. and i.v. administration of VEGF Trap, hypertension and proteinuria, are similar to those seen with other molecules that target the VEGF pathway. In the s.c. VEGF Trap phase I trial, significant radiographic improvement was observed in a patient with heavily pretreated NSCLC. Ongoing phase I trials are evaluating combinations of VEGF Trap with platinum-based doublets and single-agent docetaxel. The activity of single-agent VEGF Trap in NSCLC is being assessed in a multicenter phase II trial.

This article has been cited by other articles:

				J. P. Cooke Critical Determinants of Limb Ischemia J. Am. Coll. Cardiol., July 29, 2008; 52(5): 394 - 396. [Full Text] [PDF]

				A. Zanini, A. Chetta, and D. Olivieri Review: Therapeutic perspectives in bronchial vascular remodeling in COPD Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 179 - 187. [Abstract] [PDF]

				V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. B. Kopp, M. G. Kabir, P. H. Backx, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy N. Engl. J. Med., March 13, 2008; 358(11): 1129 - 1136. [Abstract] [Full Text] [PDF]